Shanghai Eye Disease Prevention and Treatment Center (SEDPTC)
Shanghai, Shanghai Municipality, 200336, China
NCT Number: NCT07120737
Children aged 7-14 years with high myopia were randomly assigned to a control group or an intervention group at a 1:1 ratio. The intervention group wore H.A.L.T. MAX lenses for at least 10 hours per day for 2 years, and the control group wore ordinary single-vision (SV) spectacles for at least 10 hours per day. At the 1-year follow-up examination (6-month visit), control subjects whose equivalent spherical diopter change (SER) was ≥0.75 D were switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) subjects will be replaced with H.A.L.T. MAX defofocus frames for at least 10 hours per day until the end of year 2. And continue to wear it for at least 10 hours per day. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, and to provide a scientific basis for the formulation and practice of public health programs for delaying myopia progression and the risk of blindness and visual impairment caused by high myopia.
Trial opening soon.
Get Notified7 year–14 year
All sexes
Interventional
Not applicable
Shanghai, Shanghai Municipality, 200336, China
In a 2-year randomized controlled study, the intervention group wear H.A.L.T. MAX spectacle lenses for more than 10 hours a day for 2 years. During the first year, the control group wore conventional single-vision (SV) spectacles for at least 10 hours per day. At the 6-month follow-up visit, if the spherical equivalent refraction (SER) change in the control group (SV) participants was ≥0.75 D, they were switched to H.A.L.T. MAX spectacle lenses until the end of the second year. In the second year, all remaining control group (SV) participants were transitioned to H.A.L.T. MAX defocus spectacle lenses and continued wearing them until the study concluded. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses for delaying myopia in children with high myopia, and to provide a scientific basis for the development of prevention strategies for children with high myopia.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression
Time frame: at the end of 1-year
the proportion of change in SER of ≤ -0.75 (D) at the end of 1-year in both groups
Time frame: at the end of 1-year
The proportion of change in AL of ≥ 0.34 mm at the end of 1-year in both groups
Time frame: at the end of 1-year
visual quality, assessed by specify questionnaire.
Time frame: 1 year
Number of participants with adverse events (e.g., headache, dizziness) attributed to lens wear.
Time frame: at the end of 2-year
Changes in SER and AL in the SVL switch over group in the second year.
Time frame: at the end of 2-year
Changes in choroidal thickness from baseline in the intervention and control group by OCT.
Contact information is provided by the study sponsor or research team.
Shanghai Eye Disease Prevention and Treatment Center
Other
Efficacy and Safety of Spectacle Lenses With Maximized Highly Aspherical Lenslets Target Technology (H.A.L.T. MAX) on High Myopia Control in Children and Adolescents: a Randomized Controlled Research
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06616506
Automatic Judgement, Behavior
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04110067
Eye Diseases, High Myopia
Münster, North Rhine-Westphalia, Germany
View Trial DetailsNCT07724210
Eye Diseases, Myopia
Beijing, Beijing Municipality, China
View Trial DetailsNCT07406906
Eye Diseases, Myopia
Hong Kong
View Trial Details